Patents by Inventor Elena PISKOUNOVA

Elena PISKOUNOVA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lin28-mediated control of let-7 biogenesis
    Patent number: 10865252
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: December 15, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • LIN28- MEDIATED CONTROL OF LET-7 BIOGENESIS
    Publication number: 20200031950
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Application
    Filed: March 6, 2018
    Publication date: January 30, 2020
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • TREATMENT FOR CANCER METASTASIS
    Publication number: 20180312844
    Abstract: The present disclosure relates to combination therapies for melanoma using anti-folates and/or inhibitors of ALDH1L1, ALDH1L2, or MTHFD1, and in particular, metastatic melanoma. Drugs for use in such combination include MEK inhibitors, BRAF inhibitors and cardiac glycosides.
    Type: Application
    Filed: April 12, 2016
    Publication date: November 1, 2018
    Applicant: The Board of Regents of the UIniversity of Texas System
    Inventors: Sean MORRISON, Elena PISKOUNOVA
  • LIN28- MEDIATED CONTROL OF LET-7 BIOGENESIS
    Publication number: 20180273638
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Application
    Filed: March 6, 2018
    Publication date: September 27, 2018
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Lin28-mediated control of let-7 biogenesis
    Patent number: 9938354
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogenesis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: April 10, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • Combination treatments for melanoma
    Patent number: 9561245
    Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: February 7, 2017
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Sean Morrison, Elena Piskounova, Ugur Eskiocak
  • LIN28-MEDIATED CONTROL OF LET-7 BIOGENESIS
    Publication number: 20140328858
    Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
  • TREATMENTS FOR MELANOMA
    Publication number: 20140080772
    Abstract: The present invention relates to mono- and combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include RO 31-8220, bafetinib, and cardiac glycosides.
    Type: Application
    Filed: September 5, 2013
    Publication date: March 20, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Sean MORRISON, Elena PISKOUNOVA, Ugur ESKIOCAK
  • COMBINATION TREATMENTS FOR MELANOMA
    Publication number: 20140066392
    Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.
    Type: Application
    Filed: September 5, 2013
    Publication date: March 6, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Sean MORRISON, Elena PISKOUNOVA, Ugur ESKIOCAK